Design Therapeutics

Design Therapeutics

Design Therapeutics

Overview
Date Founded

2017

Headquarters

6005 Hidden Valley Road,Suite 110,Carlsbad, CA 92011

Type of Company

Public

Employees (Worldwide)

15

Industries

Other Business & Consulting Services
Medical Support Services
Biotechnology

Company Description

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded on December 18, 2017 by Pratik Shah and Aseem Z. Ansari and is headquartered in Carlsbad, CA.

Executives & Employees

Co-Founder

President, Chief Executive Officer & Director

Chief Operating Officer

Board of Directors

Co-Founder at Design Therapeutics

Co-Founder at Trius Therapeutics, Inc.

President, Chief Executive Officer & Director at Design Therapeutics

Former Consultant at Bain & Co., Inc.

Managing Director at Quan Capital Management LLC

Former Executive Chairman at Mirati Therapeutics, Inc.

Managing Partner & Chief Investment Officer at Logos Global Management LP

Paths to Design Therapeutics
Potential Connections via
Relationship Science
You
Design Therapeutics
Owners & Shareholders
Details Hidden

Cormorant Asset Management manages a hedge fund and a private equity fund that focus on investments in the healthcare sector. The firm employs a fundamental, research intensive approach that focuses on primary research to identify investment opportunities.The objective of the hedge fund is to generate superior risk-adjusted returns with low market correlation. Cormorant seeks to accomplish this objective primarily through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. The firm invests substantially, but not solely, in publicly traded equity securities in the healthcare and life science industries.The private equity fund’s investment objective is to generate significant long-term capital appreciation by creating or investing in market innovative companies in the biotechnology and life sciences marketplace. Cormorant expects to achieve this objective by primarily investing in “crossover” (or mezzanine) round or pre-IPO portfolio companies in the biotech, medical device, diagnostics, generics, pharmaceutical, specialty pharmaceutical and life science research tool sectors. Cormorant, may also invest in portfolio companies through PIPEs and in start-up portfolio companies, including start-ups organized, managed and funded with Cormorant’s or their affiliates’ proprietary capital.

Details Hidden

Cormorant Asset Management manages a hedge fund and a private equity fund that focus on investments in the healthcare sector. The firm employs a fundamental, research intensive approach that focuses on primary research to identify investment opportunities.The objective of the hedge fund is to generate superior risk-adjusted returns with low market correlation. Cormorant seeks to accomplish this objective primarily through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. The firm invests substantially, but not solely, in publicly traded equity securities in the healthcare and life science industries.The private equity fund’s investment objective is to generate significant long-term capital appreciation by creating or investing in market innovative companies in the biotechnology and life sciences marketplace. Cormorant expects to achieve this objective by primarily investing in “crossover” (or mezzanine) round or pre-IPO portfolio companies in the biotech, medical device, diagnostics, generics, pharmaceutical, specialty pharmaceutical and life science research tool sectors. Cormorant, may also invest in portfolio companies through PIPEs and in start-up portfolio companies, including start-ups organized, managed and funded with Cormorant’s or their affiliates’ proprietary capital.

Recent Transactions
Details Hidden

Design Therapeutics issued USD Common Stock

Details Hidden

Design Therapeutics raised money in a private placement transaction

Transaction Advisors
Escrow Agent

Advised onDesign Therapeutics issued USD Common Stock

Legal Advisor

Advised onDesign Therapeutics issued USD Common Stock

Underwriter

Advised onDesign Therapeutics issued USD Common Stock

Legal Advisor

Advised onDesign Therapeutics issued USD Common Stock

Clients

TO TREAT AND CURE FRIEDREICH'S ATAXIA BY ADVANCING RESEARCH, AWARENESS AND PARTNERSHIPS.

The Government of the United States of America is the federal government of the republic of fifty states that constitute the United States, as well as one capital district, and several other territories. The federal government is composed of three distinct branches: legislative, executive and judicial, whose powers are vested by the U.S. Constitution in the Congress, the President, and the federal courts, including the Supreme Court, respectively.

Key Stats and Financials As of 2020
Market Capitalization
$1.46B
Total Enterprise Value
Earnings Per Share
$-0.15
Total Equity
$34M
Total Debt
$0
EBITDA
$-8.55M
Net Profit
$-8.28M
Revenue
$0
Investors
Details Hidden

Logos Global Management LP is a multi-national private company located in San Francisco, CA, that provides investment advice. The firm was founded in 2019 by Arsani Hany William, who has been the CEO since then.

Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Intellia Therapeutics, Inc. Biotechnology - Cambridge, MA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Editas Medicine, Inc. Biotechnology - Cambridge, MA

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Design Therapeutics. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Design Therapeutics's profile does not indicate a business or promotional relationship of any kind between RelSci and Design Therapeutics.